{"slideshow_credits": null, "snippet": "China sought to make an example of GlaxoSmithKline in a case that involved bribery of doctors and investigators and ended with guilty pleas and record penalties....", "abstract": "Chinese government's harsh legal crackdown on misconduct by GlaxoSmithKline, which included fraud and bribery, reflects country's increasingly assertive approach to multinational companies on its soil; case of Peter Humphrey, who was arrested in China while working as corporate investigator for pharmaceutical company, cited (Series: China Rules).", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "David", "role": "reported", "lastname": "BARBOZA", "rank": 1, "organization": ""}], "original": "By DAVID BARBOZA"}, "web_url": "http://www.nytimes.com/2016/11/02/business/international/china-rules-glaxo-bribes-sex-tape-whistleblower-cautionary-tale.html", "lead_paragraph": "China sought to make an example of GlaxoSmithKline in a case that involved bribery of doctors and investigators and ended with guilty pleas and record penalties.", "headline": {"print_headline": "China Tightens Its Grip, and Glaxo Pays a Price", "main": "Drug Giant Faced a Reckoning as China Took Aim at Bribery", "content_kicker": "China Rules", "kicker": "China Rules"}, "_id": "58191e6d7c459f606398d030", "word_count": "3473", "multimedia": [{"height": 126, "url": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 479, "url": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-articleLarge.jpg", "legacy": {"xlarge": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "479"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/11/02/business/02CHINAGLAXO/02CHINAGLAXO-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-11-01T22:59:47Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "glocations", "value": "China", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Series", "is_major": "Y", "rank": "12"}, {"name": "organizations", "value": "GlaxoSmithKline PLC", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Bribery and Kickbacks", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Frauds and Swindling", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Whistle-Blowers", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Fines (Penalties)", "is_major": "N", "rank": "6"}, {"name": "persons", "value": "Humphrey, Peter", "is_major": "Y", "rank": "7"}, {"name": "persons", "value": "Reilly, Mark", "is_major": "N", "rank": "8"}, {"name": "persons", "value": "Shi, Vivian", "is_major": "N", "rank": "9"}, {"name": "organizations", "value": "ChinaWhys", "is_major": "N", "rank": "10"}], "blog": [], "subsection_name": "International Business", "type_of_material": "News"}